LENZ Therapeutics: Buy Rating Affirmed Amid Overreaction to Isolated Adverse Event
I'm PortAI, I can summarize articles.
Analyst Matthew Caufield from H.C. Wainwright reaffirms a Buy rating for LENZ Therapeutics, maintaining a $56 price target. Despite a reported adverse event involving VIZZ eye drops, Caufield views it as an isolated case due to the patient's pre-existing retinal issues. He believes the market overreacted to this incident. Caufield is confident in the product's safety with proper patient screening and anticipates successful market adoption. Citi also maintains a Buy rating with a $52 target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments